Alnylam Pharmaceuticals has reported topline data from the Phase II clinical trial of investigational ribonucleic acid interference (RNAi) therapeutic, cemdisiran (ALN-CC5), to treat immunoglobulin A nephropathy (IgAN). 

Acting on the C5 component of the complement pathway, cemdisiran is being developed in partnership with Regeneron Pharmaceuticals.

The double-blind, randomised, multicentre, placebo-controlled trial analysed the safety and efficacy of cemdisiran in adult IgAN patients. 

It enrolled 31 adults aged between 18 and 65 years and categorised them into a 2:1 ratio to receive cemdisiran or placebo. 

According to the findings, at week 32, cemdisiran offered a 37% mean decline from baseline in the 24-hour urine protein to creatinine ratio versus placebo, the trial’s primary endpoint and a key prognostic marker of progression of the disease. 

Measures of proteinuria, variation in hematuria, percent of subjects with partial clinical remission and frequency of adverse events were included as the trial’s secondary endpoints.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The results of secondary endpoints were in line with cemdisiran’s therapeutic benefit in IgAN. 

No serious or severe adverse events (AEs) linked to the drug or any substantial drug-associated safety signals were reported in the trial. 

The overall safety and tolerability profile of cemdisiran support the continued clinical development of the drug.

Alnylam Pharmaceuticals Cemdisiran programme vice-president and programme leader Sonalee Agarwal said: “We are encouraged by these topline results with cemdisiran demonstrating what we believe to be clinically meaningful reductions in proteinuria – an important prognostic factor in IgA nephropathy.

“Given the limited treatment options and significant unmet need in IgAN, we, together with our partners at Regeneron, are formulating our plans for the Phase IIII clinical development of cemdisiran.”

In December last year, the company initiated a Phase II trial of lumasiran in people with recurrent kidney stone disease and higher urinary oxalate levels.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.